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Fulminant and severe viral hepatitis are frequently associ-
ated with mutant hepatitis B virus (HBV) strains. In this
study, the genetic background of a viral strain causing
severe subfulminant outcome in heart-transplanted patients
was studied and compared with viral hepatitis B strains that
were not linked to severe liver disease in the same setting. A
total of 46 patients infected nosocomially with HBV geno-
type A were studied. Five different viral strains were
detected, infecting 3, 9, 5, 24, and 5 patients, respectively.
Only one viral strain was found to be associated with the
subfulminant outcome and 3 patient deaths as a conse-
quence of severe liver disease. The remaining 43 patients
with posttransplantation HBV infection did not show this
fatal outcome. Instead, symptoms of hepatitis were gener-
ally mild or clinically undiagnosed. Comparison of this
virus genome with the four other strains showed an
accumulation of mutations in the basic core promoter, a
region that influences viral replication, but also in hepatitis
B X protein (HBX) (7 mutant motifs), core (10 mutant
motifs), the preS1 region (5 mutant motifs), and the
HBpolymerase open reading frame (17 motifs). Some of
these variations, such as those in the core region, were
located on the tip of the protruding spike of the viral capsid
(codons 60 to 90), also known in part as an important HLA
class II–restricted epitope region. These mutations might
therefore influence the immune-mediated response. The
viral strain causing subfulminant hepatitis was, in addition,
the only strain with a preCore stop codon mutation and,
thus, hepatitis B e antigen (HBeAg) expression was never
observed. The combination of these specific viral factors is
thought to be responsible for the fatal outcome in these
immune-suppressed heart-transplant recipients. (HEPATOL-
OGY 1999;29:1876-1883.)
The clinical consequences of a hepatitis B virus (HBV)
infection include a wide spectrum of different forms of liver
injury, ranging from acute, self-limiting infection or chronic
hepatitis with progression to cirrhosis and liver failure, to an
asymptomatic chronic carrier state. The most severe outcome
is described as fulminant hepatitis (FH), in which hepatocyte
death is so extensive that less than 30% of the patients
survive.1 There is ample evidence that HBV variants with
preCore stop codon mutations, unable to express the hepati-
tis B e antigen (HBeAg), as well as variants with several
mutations in the regulatory region enhancer II/Core pro-
moter, may be associated with severe and fulminant out-
come,2-8 and that these mutants might have an enhanced
replication rate.9 There are several other reports describing
variants in other HBV genes (preS, Core, hepatitis B X protein
[HBX]) that have been associated with a FH outcome.10-15 But
other data indicate that a specific genomic mutational pattern
has not yet been defined,7 and that the preCore mutations by
themselves were not sufficient to explain the FH out-
come.16,17
Because HBV is not directly cytopathic, or at least not
highly cytopathic for the infected hepatocyte, disease patho-
genesis is thought to be related to the immune response to
HBV-encoded antigens.18 Clearance of HBV infection was
found to be associated with the HLA class II–restricted T-cell
epitopes;19 but HLA class I–restricted epitopes of cytotoxic T
lymphocytes are also involved.1,18 In FH, this immune
reaction is extremely aggressive, resulting in massive hepato-
cellular necrosis and liver failure. Heart-transplantation (HT)
patients are under cellular and humoral immune suppres-
sion, and this immune suppression is expected to down-
modulate the antiviral response as well. The development of
subacute liver failure under these conditions can therefore be
considered as remarkable. Nevertheless, FH in such immune-
suppressed patients has been reported recently.11
In this study, the genotypic variations of the different HBV
strains circulating in a HT unit are described. Among the 86
HBV-infected transplantation patients, 46 were carrying HBV
genotype A strains, and 3 of them died as a consequence of
severe sub-FH. These 3 patients were infected with the same
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unique virus. Analysis of the genetics of this particular HBV
strain showed several variant codon positions not found in
the HBV strains with the same viral genotype in the same HT
settings, but with a non–sub-FH outcome.
PATIENTS AND METHODS
Patients
From 1984 to 1994, a total of 770 HTs were performed at the
Pitie´-Salpeˆtrie`re Hospital in Paris, France. A high prevalence of
posttransplantation HBV infection was observed in the heart recipi-
ents, because 86 (11.5%) recipients became infected. The 3 patients
described in detail in this article were under immune-suppressive
regimens consisting of prednisone, cyclosporine, and azathioprine;
all 3 patients were negative for HBV markers before transplantation,
and none of them was vaccinated.
Nosocomial Transmission of HBV. A case-control study was con-
ducted.20 Briefly, in the settings under investigation, the risk of
acquiring an HBV infection increased only significantly with the
number of endomyocardial biopsies (EMB), suggesting nosocomial
transmission associated with this procedure. Careful data analysis
excluded other risk factors (such as other hepatitis viruses, alcohol
abuse) as being of any considerable impact on the outcome. One of
the patients (P1) had a severe chronic course of liver disease, and 2
others (P2 and P3) had fatal subfulminant liver failure. Serological
and transplantation details are given in Fig. 1, including the days of
EMB. It is very likely that sub-FH patients P2 and P3 were infected
by the same HBV viral strain, because P1 and P2 had an EMB in the
same session on June 6, 1992, and P1 and P3 on July 7, 1992
(Fig. 1).
Patient 1. A 60-year-old man underwent transplantation in August
1991. HBV markers became positive from December 1991 onward.
In February 1992, alanine transaminase levels were elevated, and
HBV-DNA levels were high. In June 1992, liver biopsy showed
chronic active hepatitis without cirrhosis. Retrospective analysis
showed that approximately 70% of the hepatocytes stained positive
for hepatitis B core antigen (HBcAg) in an immunohistochemical
protocol. In May 1993, the patient was admitted to the heart-chest
surgical intensive care unit with a high fever (39°C); physical
examination showed jaundice and ascites. Echocardiography ruled
out heart failure, and liver function tests were elevated. He died from
decompensated cirrhosis with sepsis.
Patient 2. A 54-year-old man underwent transplantation in Janu-
ary 1989 for dilated cardiomyopathy. HBV markers became positive
from September 1992 onward (Fig. 1). Upon admission in Decem-
ber 1992, liver function tests were elevated, without edema or
hepatic encephalopathy, but ultrasonography showed an enlarged
liver and mild ascites. The patient developed stage II hepatic
encephalopathy with worsening liver function tests. He died in
January 1993. Postmortem liver biopsy showed marked and exten-
sive necrosis and portal and intralobular fibrosis with lymphoid and
polymorphonuclear cell infiltrates. This postmortem material was
negative for HBcAg in immunohistochemical analysis.
Patient 3. A 48-year-old man underwent transplantation in July
1991 for dilated cardiomyopathy. He had had several episodes of
rejection that responded to high-dose steroids. HBV markers became
positive from June 1993 onward, with elevated liver function tests.
Jaundice occurred in August 1993. Upon admission in September
1993, the physical examination showed edema and ascites, no signs
of hepatic encephalopathy, but liver tests worsened. Upper gastroin-
testinal endoscopy showed grade II esophageal varices. Echocardiog-
raphy and myocardial biopsy ruled out graft rejection. A first
transjugular liver biopsy showed portal fibrosis, piecemeal and
lobular necrosis, and a portal infiltrate. The clinical course showed
an increase of the ascites and renal impairment. A second liver
biopsy showed massive necrosis, extensive fibrosis, and regenerative
nodules. Approximately 10% of the hepatocytes stained positive for
HBcAg. Hepatic encephalopathy occurred, followed by a variceal
hemorrhage, with the patient dying of multiorgan failure in October
1993.
Source of Infection (Heart-donor) for Patient 1. Patient 1 had decom-
pensated heart insufficiency and underwent emergency transplanta-
tion with a heart from a person who died in an automobile accident.
Retrospective analysis showed that the heart donor was hepatitis B
FIG. 1. Time line for the 3 patients with sub-FH. Serological markers are indicated.
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surface antigen (HBsAg)-positive and HBeAg-negative. The kidney
from the same donor was also transplanted in another patient, but
this recipient was vaccinated against HBV, and HBV infection was
not subsequently established.
Immunohistochemical HBcAg Staining
The immunohistochemical study of the expression of HBcAg was
performed on deparaffinized liver tissue sections by using the
avidin-biotin-peroxidase complex method (anti-HBc antibody from
DAKO SA, Glostrup, Denmark; ABC Elite Kits from Vector Laborato-
ries, Burlingame, CA).
Serological Assays
HBsAg, anti-HBc, and anti-HBs antibodies (Ab) were assayed
using commercial enzyme immunoassays (EIA, Abbott, Chicago, IL;
Organon Technika, Boxtel, the Netherlands). HBsAg-positive samples
were further investigated for the presence of HBeAg, anti-HBe Ab,
and anti-HBc Ab (Abbott; Organon Technika; Vidas, Bio-Me´rieux,
Marcy, France). HBV DNA in serum was measured by using the
Hybrid Capture Assay (Murex, Dartford, UK).
Extraction of HBV DNA
One hundred microliters of serum was diluted with another 100
µL of phosphate-buffered saline. From this mixture, HBV DNA was
isolated after a proteinase K digestion by means of binding to glass
fibers (High Pure PCR Template preparation Kit, Boehringer, Mann-
heim, Germany). HBV DNA was eluted from the glass fiber column
in 200 µL H2O, and stored at 220°C until use.
Polymerase Chain Reaction Amplification and Sequencing
Two different amplicons were generated: 1) a complete genome
amplicon; and 2) the region covering the open reading frame of
HBX, preCore, and Core (indicated as X/pC/C). For 1): complete
genome amplification was performed on 10 µL of HBV-DNA extract,
essentially as described,21 using amplification primers HBPr 108:
58-TTTTTCACCTCTGCCTAATCA-38 (sense) and HBPr 109: 58-
AAAAAGTTGCATGGTGCTGG-38 (antisense). Both primers are
located in the preCore open reading frame. For 2): the X/pC/C was
amplified from 10 µL DNA extract using amplification primers HBPr
110: 58-CCGTCTGTGCCTTCTCATCTGCCGG -38 (sense) and HBPr
304 58-ACTTAGAGGAATAAAGCCC-38 (antisense). The samples
were thermocycled for 40 rounds at 94°C for 1 minute, 48°C for 1
minute, and 72°C for 1 minute. Amplification products were
visualized and quality-controlled on agarose gel, and sequenced
using dideoxy sequencing (ABI prism dye terminator protocol;
Perkin Elmer, ABD, Foster City, CA).
Nucleotide Sequences
Sequence information was submitted to Genbank and is available
under accession numbers AF090838 to AF090842. Complete ge-
nomes were retrieved from the database and included in the
phylogenetic analysis and phylogenetic tree construction using the
software program GeneCompar (Applied Maths, Kortrijk, Belgium).
Accession numbers of sequence isolates used in this approach are
indicated in Fig. 3. The consensus genotype A sequence was
generated by making alignments of HBV genotype A–Genbank
available sequences (excluding FH strains); each nucleotide position
was checked, and the most common genotype-specific nucleotide
was retained. This consensus sequence is artificial (available upon
request), but shows the lowest phylogenetic distance to all other
genotype A isolates.
Research Line Probe Assay for PreCore Variability
Codon 28 (cd28) and codon 29 (cd29) showed some genetic
variability with consequences in HBeAg expression. Combinations
of the amino acids trypthophan (W), glycine (G), stop codon (X),
and asparagine (D) can occur at these codon positions. To detect this
variability, a research line probe assay (LiPA) was designed with
specific probes covering the following motifs: 1) 28W-29G;
2) 28X-29G; 3) 28W-29D; and 4) 28X-29D. In addition, two specific
probes for the preCore promoter region covering the important
variability at nucleotides 1762 and 1764 were also prepared. One
additional probe covering the consensus nucleotide sequence of
the preCore ATG region was designed (Fig. 2). Probes were applied
on a nitrocellulose membrane as described.22 HBV preCore was
amplified from 10 µL DNA extract with biotinylated primers HBPr
FIG. 2. A LiPA HBV preCore.
The strip contains 7 probes, the
position of which is indicated at
right. CC, conjugate control; AC,
HBV amplification control. P1,
sub-FH patient 1; P2, sub-FH pa-
tient 2; P3, sub-FH patient 3. 28X,
translational stop at codon 28 of
preCore, G, glycine; D, asparagine;
W, tryptophan. Sub-FH P1 contains
a mixture at codon 29; this mixture
was detectable by sequencing, but
was clearly confirmed in this LiPA.
Absence of reactivity on the preCore
ATG region probe (G5 samples) is
indicative of the presence of muta-
tions. However, it is impossible to
predict the correct mutation site.
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70:58-TACTTCAAAGACTGTGTGTTTA-38 (sense), and HBPr 7:
58-CTCCACAGTAGCTCCAAATTC-38 (antisense). LiPA test perfor-
mance was identical as described for INNO-LiPA HCV II.22
Determination of the HLA Type
HLA DRB types were determined on serum DNA by using the
LiPA-HLA-DRB decoder (Innogenetics, Gent, Belgium). The 3
patients belonging to G1 were typed: Patient P1: DRB1*0306 1
DRB1*0401; Patient P2: DRB1*1501 1 DRB1*1501; Patient P3:
DRB1*1601 1 DRB1*11.
RESULTS
Genotype Analysis of the HBV-Infected Heart-Transplanted Pa-
tients. HBV-DNA samples from the 86 HBsAg-positive HT
patients were polymerase chain reaction–amplified in the
HBsAg region. A total of 76 were found to be polymerase
chain reaction–positive and could be genotyped using the
previously described LiPA technology.23 Of these, 46 were
infected with an HBV genotype A strain, and the remaining
30 showed a genotype D profile. Because the 3 patients with
the severe sub-FH outcome could be grouped together with
the genotype A population, we continued the analysis on this
group; genotype D samples were not analyzed further.
All genotype A samples were tested on research versions of
the HBsAg genotyping LiPA,23 and the preCore LiPA (Fig. 2).
Based on the combination of observed LiPA variability at 1)
HBsAg codon 143 (methionine or threonine), 2) the preCore
promoter region (nucleotide positions 1762 and 1764), 3) the
variability in the vicinity of the ATG of preCore, and 4)
codons 28 and 29 of preCore, we concluded that five different
viral HBV strains (indicated as G1 to G5) were involved in
this nosocomial transmission. The 3 sub-FH patients be-
longed to G1 (Table 1).
Based on this G1-to-G5 classification, complete HBV
genome sequence analysis was performed on 1 patient isolate
from each group. Phylogenetic analysis on complete HBV
genomes confirmed that all five indeed clustered together
with reference genotype A isolates on the same branch of the
phylogenetic tree (Fig. 3), as did the artificial genotype A
consensus sequence. The complete genomes were 3,221-bp
long; the sub-FH isolate from G1 showed 1.77% dissimilarity
with the consensus genotype A sequence; G2, G3, and G4
had dissimilarities of 0.75%, 0.75%, and 0.9%, respectively,
but, surprisingly, the G5 sequence showed a 4.25% dissimilar-
ity with the consensus sequence.
In addition, another 25 sequences were determined cover-
ing the region X/pC/C (Table 1). Within each group, the
sequences that were obtained were 100% identical with the
complete genome sequence, confirming the LiPA findings
and proving that five different strains were indeed present.
The only differences in the sequences that were observed
were found in the sub-FH patients P2 and P3; these differ-
ences are clearly shown in the amino acid alignment of the
core region shown in Fig. 4A.
Amino Acid Variability in the 5 Different Genetic Groups. Table
2 summarizes the amino acid changes that were found in the
complete genomes as compared with a genotype A consensus
sequence. In total, the sub-FH G1 strain showed 46 variant
amino acids over the 7 HBV open reading frames, the G5
strain had 63 variant amino acids, while G2, G3, and G4 only
had 6, 7, and 18 variant amino acids, respectively. Within the
G1 strain, the most striking finding was the accumulation of
mutations in the HBcAg open reading frame. In all other
groups, none showed variant amino acids in HBcAg. HBX was
also found to be quite different in G1, but numerically, G5
FIG. 3. Phylogenetic tree of complete HBV genomes. Sequences are
indicated with their GenBank accession number.
TABLE 1. Overview of Results Showing Five Different HBV Strains in 46 HBV-Infected HT Patients
Group
n
Patients HBsAg*
Combined LiPA Results Sequencing Results (n5)
Promoter† cd28-cd29† ATG PreCore† X/pC/C CG Total
G1 3 T143 T1762/A1764 28X-29G‡ no mutations detectable 2 (P2, P3) 1 (P1) 3
G2 9 M143 A1762/G1764 28W-29G no mutations detectable 4 1 5
G3 5 M143 A1762/G1764 28W-29D no mutations detectable 4 1 5
G4 24 T143 A1762/G1764 28W-29G no mutations detectable 11 1 12
G5 5 T143 A1762/G1764 28W-29G mutations 4 1 5
Total 46 25 5 30
Abbreviation: CG, complete genome.
*The research HBsAg genotyping LiPA [Van Geyt et al., 1998] permits detection of the difference at codon 143 between ATG (methionne) or ACG
(threonine).
†The research preCore LiPA allows detection of promoter mutations 1762 and 1764, presence of an ATG precore consensus sequence, and cd28/cd29
variability. Examples taken from the 5 different groups are shown in Fig. 2. All 46 samples were tested for reactivity in the region of preCore translational
initiation (ATG at nucleotide position 1814). Samples from G5 having mutations in this region were not reactive in these experiments.
‡Patient 1 was infected with a mixture of viral strain having the codon 28X-29G and 28X-29D genotype; detailed in Fig. 2.
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exceeded the amount of mutations (7 amino acid changes in
G1 vs. 9 in G5). The majority of all other mutations were
found in the 844–amino acid–long polymerase, with G1
showing 17 amino acid changes, G4 showing 11 changes, and
G5 showing a total of 38 amino acid changes. Most of these
pol mutations were found in the region where the overlap-
ping reading frame of preS1 is located, and the latter is also
reflected in the increased amount of mutations found in this
part of the envelope protein.
Nucleotide Changes in the Transcriptional Regulatory Regions.
For the five different viral strains, nucleotide changes in the
core upstream regulatory sequence (CURS), the basic core
promoter (BCP), and the encapsidation signal (e) are detailed
FIG. 4. Sequence alignment of representative strains of the 5 HBV genotype A infection groups. Consensus A: nucleotide and deduced amino acid
sequence of the artificial consensus genotype A strain (see Patients and Methods). (A) Amino acid sequence alignment of preCore/Core region. The a-helical
and important antigenic regions are indicated. (B) Nucleotide sequence alignment of the regulatory regions, with indication of the different motifs (CURS,
ENHII, BCP, e).
TABLE 2. Summary of Amino Acid Changes in 5 HBV Genotype A Strains
Compared With an Artificial Consensus Genotype A Sequence
G1 G2 G3 G4 G5
PreS1 5 0 1 5 7
PreS2 2 0 0 2 6
HBsAg 3 1 1 0 2
HBcAg 10 0 0 0 0
PreCore 2 0 1 0 1
HBX 7 1 1 0 9
HBpol 17 4 3 11 38
Total 46 6 7 18 63
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in Fig. 4B. An accumulation of four nucleotide variations
occurred in the BCP of the sub-FH strains, but not in the
non-FH strains. Remarkably, the 5 patients in G5 showed 6
variant nucleotides at positions covering the enhancer II
(ENHII), the BCP, and the encapsidation signal.
DISCUSSION
In this study, we dealt with essentially two issues: 1) a
patient-to-patient transmission in a heart-transplantation
setting, and 2) the pathogenic potential of a mutated HBV
strain. Concerning patient-to-patient transmission, a total of
11.5% of the transplanted patients became infected (mostly
after transplantation). A previously published investigation20
showed that, by using statistical methods, the most likely way
of transmitting the virus nosocomially was via an EMB
procedure. As further proof, we found that during the course
of analyzing the patients’ files, these 3 sub-FH patients
underwent such an EMB procedure on the same day. After
implementation of special safety regulations in 1995 (de-
scribed in Rosenheim et al.20), the incidence of new HBV
infections was reduced to zero. Concerning the pathogenic
potential of the HBV strains involved in this epidemic
situation, we compared the nucleotide and deduced amino
acid sequences of five viral HBV strains belonging to geno-
type A, and that were responsible for a total of 46 infections.
Three of these patients died from severe sub-FH, while the
remaining 43 showed a chronic but mild hepatitis. Further-
more, as compared with an artificial genotype A consensus
sequence, it was shown that G1 (the sub-FH strain) was
clearly different in many regions from the control strains G2,
G3, and G4, but another viral strain G5, causing 5 infections,
was even more divergent from the consensus strain than G1.
The most intruiging questions that emerged were: ‘‘Why did
this G5 strain not cause severe sub-FH in comparable
settings?’’ and ‘‘What is so special about the G1 genotype that
enables it to cause severe sub-FH?’’
Three major differences were observed that might be
important to understand the hidden pathogenic potential of
the sub-FH strain: First, only the G1 strain was unable to
express HBeAg because of the presence of a translational stop
in the preCore open reading frame at codon 28 (TGG to TAG)
(Fig. 2). Second, G1 had up to 10 mutations in HBcAg; this
region was completely conserved in the four other groups,
including G5 (Fig. 4A). Third, some very typical mutations in
the ENHII and the BCP were present in G1, including the
A1762T and the G1764A mutations (Fig. 4B). The particular
importance of each of these observations can be considered as
follows:
x With respect to HBeAg expression, G1 strains are preCore-
defective mutants and cannot produce HBeAg. This HBeAg
might otherwise prevent cytotoxic T lymphocytes from
attacking the target HBcAg, because these two antigens share
the same T-cell epitopes.24 Therefore, hepatocytes harboring
the replicating virus expressing the mutant HBcAg might be
attacked directly by cytotoxic T lymphocytes, resulting in an
extensive necrosis. This appears to be in agreement with the
findings of the immunohistochemical HBcAg stainings ob-
served in 2 patients (1 sample was negative, but this might be
the result of the poor quality of the postmortem biopsy).
However, preCore-deficient variants do not always cause
FH,16,17 and not all FH patients harbor preCore-deficient
viruses.9,25 It is obvious that one or more additional factors
are required to lead to a sub-FH outcome. A remarkable
observation was present with respect to HBeAg-related serol-
ogy of patient P1, showing a transient presence of anti-HBe
antibodies. This might be a response to a minor population of
precore cd28 wild-type virus expressing HBeAg, but this
population remains undetectable in molecular biology proto-
cols. It is not known whether such a minor population can
induce a detectable level of antibodies. Alternatively, the
anti-HBe Ab are transmitted during transplantation or by
blood transfusion.
x Concerning HBcAg mutations, a strong association of
core mutations and preCore codon 28 variants was described
in patients with chronic hepatitis.26 These HBcAg mutations
were predominantly detected around the time of HBeAg
clearance, when liver disease is most active, and were mostly
found in the middle of the core gene, but not in the
C-terminal part. The middle of the core gene (residues 60 to
90) was found to be located at the tip of the protruding spikes
of the viral capsid, and therefore surface-exposed.27 This
region contains much of the HBcAg-related antigenicity.1,27,28
Features of core mutations in chronic patients were present in
the sub-FH G1 strain: mutations were found mainly in the
middle of core (residues 64 to 79), and they were associated
with a precore translational stop codon. Of special interest is
the P79Q mutation, because this mutation is located on top of
the antiparallel a-helical hairpin of HBcAg.25 Because the
proline residue at position 79 is very conserved,25 most likely
because of its structural importance, this P79Q mutant may
influence the antigenic and conformational character of the
protruding spike. In addition, these mutations were also
located in previously recognized epitopes.18 Mutations in the
core regions were previously described and were linked to
fulminant outcome.14,25
x In terms of transcriptional regulation, the HBX open
reading frame encodes for the X protein, but also contains the
core promoter and the ENHII complex, DR1 and DR2, thus
obligating the entire nucleotide sequence of the X region to
participate in gene regulation.29 X protein is a multifunctional
protein that acts either in the cytoplasm by activation of gene
expression via several pathways, or in the nucleus, where it
interacts directly with transcription factors and DNA repair
machinery.29,30 The latter might play a role in hepatocellular
carcinogenesis. Some critical mutations might enhance or
disrupt these functions. The majority of the mutations found
in this study, both for G1 as for G5, are located in the
previously described four hotspots (aa30 to aa47; aa87 to
aa94; aa116 to aa119; and aa130 to aa131) of the X protein.29
The three most important mutations that were previously
linked to FH are T1753C, A1762T, and G1764A. These
mutations are located within the nuclear protein-binding
DNA sequences of the core promoter and ENHII (Fig. 4B).
These mutations might alter the transcriptional activity of
HBV by changing the binding affinity of the nuclear proteins
for the mutated sequences. In addition, in vitro experiments
showed that the double mutant at 1762 and 1764 results in a
reduced preCore gene expression and in an increase in
progeny virus replication.31 However, Sterneck et al.32 com-
pared the replication competence and expression levels of
HBsAg and HBeAg of 7 FH genomes, and showed that,
compared with the wild-type virus, FHB strains produced
similar or slightly lower levels of replicative intermediates
HEPATOLOGY Vol. 29, No. 6, 1999 STUYVER ET AL. 1881
and extracellular viral particles.32 The same authors therefore
suggested an additional role of other viral factors in FHB.
Irrespective of this, the changes A1762T and G1764A are
responsible for the three amino acid changes, I127T, K130M,
and V131I, which might in turn result in an altered transacti-
vation activity of the X protein. The mutations at 1762 and
1764 are also frequently found in chronic HBeAg-positive,
and in anti-HBe–positive patients (our observations and
Takahashi33), and are therefore in themselves insufficient to
explain the subfulminant outcome, as is the case for the
preCore stop codon mutation. The C1858T mutation is a
compensatory mutation to restabilize the encapsidation sig-
nal, which was destabilized as a result of the selection of the
mutant G1896A. The latter is a typical genotype A event.34
However, none of these critical mutations were found in the
G5 strain; mutations there were most likely located in those
regions tolerating alterations both on the X protein level as
well as on the regulatory sequence level.
Karayiannis et al.35 investigated the transmission of a FH
virus in sets of patients and found that the nucleotide
sequence of the patient with FH was identical to that
observed in the asymptomatic source of the infection.35 This
suggested that the severity and outcome was unrelated to any
additional variation of the HBV genome, but mainly de-
pended on host factors, and possibly the HLA environment.
In the present study, there is evidence of transmission of a
pathogenic HBV mutant during HT, but there was no
macroscopic evidence of liver disease in the heart donor, and
further microscopic and liver histological examinations were
not performed. Therefore, this heart donor must be consid-
ered as an asymtomatic carrier as well. The association with
the HLA class II locus was investigated (Patients and Meth-
ods), but no consensus HLA type was observed, rendering
these results inconclusive.
It is generally accepted that HBV is not directly cytopatho-
genic. However, it is possible that the mutations in the HBcAg
(for example, the structural important P79Q, or any other
mutation) would alter the cytopathogenicity of the virus,
especially when transmitted to a new host, i.e., from donor to
patient, or from patient to patient.
In conclusion, the following hypothetical picture emerges:
a G1 strain evolved for many years in an immune-competent
chronic carrier (the source heart donor), resulting in the
accumulation of several mutations in the preCore/Core gene,
including those in antigenic epitopes. This individual was
clinically asymptomatic and died in an automobile accident.
The heart was transplanted under emergency conditions, and
the recipient (P1) became infected with a highly mutated
HBV strain. During routine EMB, this HBV strain was
transmitted to at least two HT patients. In these HT recipi-
ents, one or more of the following factors contributed to the
lethal outcome of the sub-FH: 1) the mutated HBcAg; 2)
absence of HBeAg and absence of induction of a tolerance
phase; 3) a possible modified rate of replication caused by
BCP mutations; 4) the immune-suppressive regimen; 5) an
altered cytopathogenicity of the virus; and/or 6) special host
factors.
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